Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;94(2):645-54.
doi: 10.1016/j.fertnstert.2009.03.034. Epub 2009 Apr 18.

Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors

H Irene Su  1 , Mary D Sammel, Luke Velders, Michelle Horn, Corrie Stankiewicz, Jennifer Matro, Clarisa R Gracia, Jamie Green, Angela DeMichele
Affiliations

Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors

H Irene Su et al. Fertil Steril. 2010 Jul.

Abstract

Objective: To determine if genetic variation in chemotherapy metabolism are associated with risk of ovarian failure in breast cancer patients after adjuvant chemotherapy.

Design: Prospective cohort study.

Setting: Comprehensive cancer center.

Patient(s): Early-stage breast cancer patients who were premenopausal at cancer diagnosis and treatment.

Intervention(s): None.

Main outcomes measure(s): Chemotherapy-related ovarian failure (CROF).

Result(s): A total of 127 breast cancer subjects who were premenopausal at cancer diagnosis and underwent cyclophosphamide-based chemotherapy were genotyped for nine single-nucleotide polymorphisms (SNPs) in enzymes involved in cyclophosphamide activation (CYP3A4, CYP2B6, CYP3A5) and detoxification (GSTA1, GSTM1, GSTP1, GSTT1). Median age at chemotherapy was 43.2 years. Median follow-up after chemotherapy was 5.2 years. For the entire cohort, there was no significant association between CROF and SNPs. However, the association between CROF and SNPs was modified by age at chemotherapy. In subjects younger than 45 years old at chemotherapy, CYP3A4 *1B variants had significantly longer time to CROF than CYP3A4 *1A homozygotes in an adjusted multivariable Cox model. Age and tamoxifen use were also independently associated with CROF.

Conclusion(s): A common SNP in a cyclophosphamide drug-metabolizing enzyme appears to be related to ovarian failure after cyclophosphamide-based chemotherapy in young women with breast cancer. Larger prospective studies to validate these results should be directed toward women younger than 45 years of age at chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of cyclophosphamide activation and detoxification by durg metabolizing enzymes
Figure 2
Figure 2
Kaplan-Meier survival curves of time to CROF by genotype alone (a, c) and by genotype and age at chemotherapy (b, d)
Figure 2
Figure 2
Kaplan-Meier survival curves of time to CROF by genotype alone (a, c) and by genotype and age at chemotherapy (b, d)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ries LAG, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, et al., editors. SEER Cancer Statistics Review. National Cancer Institute; Bethesda, MD: 1975–2005. http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site 2008.
    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66. - PubMed
    1. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–29. - PubMed
    1. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992;166(3):788–93. - PubMed
    1. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–70. - PubMed

Publication types

MeSH terms